[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genprex Inc (GNPX)

Genprex Inc (GNPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,995
  • Shares Outstanding, K 10,927
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,230 K
  • EBIT $ -16 M
  • EBITDA $ -15 M
  • 60-Month Beta -0.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.40
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -14.14
  • Most Recent Earnings $-0.64 on 05/13/26
  • Next Earnings Date 08/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6242 +2.56%
on 06/11/26
0.8800 -27.25%
on 05/15/26
-0.1898 (-22.87%)
since 05/12/26
3-Month
0.6242 +2.56%
on 06/11/26
2.1200 -69.80%
on 03/16/26
-1.3198 (-67.34%)
since 03/12/26
52-Week
0.6242 +2.56%
on 06/11/26
55.0000 -98.84%
on 10/15/25
-15.0148 (-95.91%)
since 06/12/25

Most Recent Stories

More News
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients

GNPX : 0.6402 (-2.05%)
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks

GNPX : 0.6402 (-2.05%)
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Strengthens Patent Estate and Expands Protection in Another Target Market

GNPX : 0.6402 (-2.05%)
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks

GNPX : 0.6402 (-2.05%)
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

AUSTIN, Texas , April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for...

GNPX : 0.6402 (-2.05%)
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

Research on Biomarkers May Help Enrich Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials, Potentially Predicting Patient Response to REQORSA Treatment

GNPX : 0.6402 (-2.05%)
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa ® Gene Therapy

GNPX : 0.6402 (-2.05%)
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa ® Gene Therapy

GNPX : 0.6402 (-2.05%)
Genprex to Participate at BIO Europe Spring 2026

AUSTIN, Texas , March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for...

GNPX : 0.6402 (-2.05%)
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq ®

GNPX : 0.6402 (-2.05%)

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

3rd Resistance Point 0.7333
2nd Resistance Point 0.7147
1st Resistance Point 0.6774
Last Price 0.6402
1st Support Level 0.6215
2nd Support Level 0.6029
3rd Support Level 0.5656

See More

52-Week High 55.0000
Fibonacci 61.8% 34.2284
Fibonacci 50% 27.8121
Fibonacci 38.2% 21.3958
Last Price 0.6402
52-Week Low 0.6242

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.